ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).

The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis. The primary outcome were major kidney disease events, onset of kidney failure, a 50% reduction of eGFR from baseline or death from kidney related or cardiovascular causes.

Findings showed that the risk of a primary outcome event was 24% lower in the patients who had received semaglutide as compared to those who had received placebo, with similar findings from the kidney-specific outcomes. Confirmatory secondary endpoints also favoured semaglutide over placebo.

 Questions:

1. What is the importance of the FLOW trial?
2. What was the patient population and study design?
3. What are the key findings and safety outcomes?
4. What are the implications of these findings on clinical practice?
5. What are the next steps?

Recorded Remotely from Kensington, 2024.

Interviewer: Greg Guillory